EUCTR2017‐000488‐34‐IT.

Study name	Rifaximin blunted higher levels of endotoxin in cirrhosis patients: a randomized, double‐blind, short term interventional trial ‐ rifaximin in cirrhotic patient
Methods	Randomised, double‐blind clinical trial
Participants	Adults with decompensated cirrhosis (Child‐Pugh grade B or C), without overt hepatic encephalopathy at baseline
Interventions	Intervention: rifaximin 550 mg twice daily orally Control: film‐coated tablet placebo orally
Outcomes	Bacterial lipopolysaccharide concentration, thrombin generation, platelet activation indexes, adverse events, mortality, clinical outcomes Duration of intervention: 14 days Duration of follow‐up: 60 days after discontinuation of drug
Starting date	Unknown
Contact information	Stefania Basili (Sapienza‐Universita di Roma), stefania.basili@uniroma1.it, 3393452523
Notes	Monetary support: Alfa Wassermann S.p.A Trial registered: 8 June 2021 Last update: 24 August 2021 This is a mechanistic trial which may provide data of relevance on hepatic encephalopathy.